Newswise — [FORT WASHINGTON, PA — July 6, 2017] Access to high-quality, high-value cancer care is crucial for all patients with cancer. Ideally, following a cancer diagnosis, patients should have the option to choose care from an experienced, multi-disciplinary team of sub-specialists at a comprehensive cancer center that offers the latest cancer treatment and supportive care breakthroughs. Now, this freedom of choice is being threatened by narrow network insurance plans.
A new study from the Perelman School of Medicine at the University of Pennsylvania shows that these lower-cost plans reduce access to certain providers at comprehensive cancer centers, including National Comprehensive Cancer Network® (NCCN®) Member Institutions and National Cancer Institute (NCI)-Designated Cancer Centers. The study was published yesterday in the Journal of Clinical Oncology.
“Because cancer care and monitoring is costly, there are strong incentives for insurers to be selective when it comes to oncologists, excluding those who are most likely to attract the most complex and expensive cases,” the study’s lead author, Laura Yasaitis, PhD, a postdoctoral researcher at Penn said in a press release. Yasaitis and colleagues call for greater access for patients and more transparency from insurers.
“At NCCN our mission is to improve the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. To that end, we applaud Dr. Yasaitis and her colleagues for their call for improved patient access and improved transparency from U.S. payers,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “NCCN Member Institutions are home to expert physicians, superior treatment options, and quality and safety initiatives that continuously improve the cancer care in the United States and around the world.”
Looking at 2014 individual health insurance exchanges, the Penn researchers observed that oncologists affiliated with NCCN Member Institutions and NCI-Designated Cancer Centers were less likely to be included in the narrow plan. According to Yasaitis, no matter how the authors looked at the data, there was a clear trend towards exclusion.
“NCCN publishes clinical treatment guidelines that are accessible by any cancer stakeholder so that where a patient lives doesn’t determine if a patient lives,” said Carlson. “However, the experience, innovation, and expertise found at the NCCN Member Institutions and other comprehensive cancer centers throughout the country should not and cannot be discounted. Stripping patients of a right to choose a comprehensive care approach not only takes away their access to leading innovations and supportive care programs that promote better outcomes, but also stifles the innovation fostered at these leading centers that is changing the face of cancer care as we know it.”
In a previously reported 2015 survey of NCI-Designated Cancer Centers conducted with Avalere, NCCN found that 25% of the respondents were excluded by exchange plans offered by the majority of the state’s exchange carriers.1
Moreover, as noted in a 2016 NCCN Policy Report, studies have shown that patients treated at comprehensive cancer centers indeed realize better outcomes. Wolfson, et al., found that patients diagnosed with common adult-onset cancers (breast, colorectal, lung, hepatic, pancreatic, and gastric) who were not treated at NCI-Designated Comprehensive Cancer Centers had a 20-50% higher risk of mortality compared with patients treated at those centers.2
When choosing a health plan, consumers may not be aware of in-network providers, nor the cost of seeing providers out-of-network. However, when diagnosed with cancer, patients want the highest-quality care to give them the best chance of survival. To this end, NCCN believes consumers need greater education when choosing plans as well as increased network adequacy on the part of insurers and policymakers.
World-renowned experts from NCCN Member Institutions diagnose and treat patients with a broad spectrum of cancers and are recognized for dealing with complex, aggressive, or rare cancers. NCCN Member Institutions pioneered the concept of the multidisciplinary team approach to patient care and conduct innovative research that contributes significantly to understanding, diagnosing, and treating cancer. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), developed by volunteer experts from the NCCN Member Institutions are the recognized standard for clinical policy in cancer care and are often the most thorough and most frequently updated clinical practice guidelines available in any area of medicine.
For more information about NCCN, visit NCCN.org.
About the National Comprehensive Cancer Network The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.
The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.
1Pearson CF, Choe SH. Leading Cancer Centers May Be More Widely Included in Exchange Networks Than Expected. Avalere Health Web site. Available at: http://avalere.com/expertise/life-sciences/insights/leadingcancer-centers-may-be-more-widely-included-in-exchange-networks-tha. Accessed March 1, 2016.
2Wolfson JA, Sun CL, Wyatt L, et al. Impact of care at comprehensive cancer centers on outcome: results from a population-based study. Cancer 2015;121:3885–3893.